| Product Code: ETC9548386 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Sweden Antisense and RNAi Therapeutics Market Overview |
3.1 Sweden Country Macro Economic Indicators |
3.2 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Sweden Antisense and RNAi Therapeutics Market - Industry Life Cycle |
3.4 Sweden Antisense and RNAi Therapeutics Market - Porter's Five Forces |
3.5 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume Share, By End Users, 2021 & 2031F |
3.9 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Sweden Antisense and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of genetic disorders and chronic diseases in Sweden |
4.2.2 Growing demand for personalized medicine and targeted therapies |
4.2.3 Technological advancements in RNA interference (RNAi) and antisense therapy research |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in Sweden |
4.3.2 High costs associated with development and commercialization of antisense and RNAi therapeutics |
4.3.3 Limited awareness and adoption of RNA-based therapies among healthcare providers and patients |
5 Sweden Antisense and RNAi Therapeutics Market Trends |
6 Sweden Antisense and RNAi Therapeutics Market, By Types |
6.1 Sweden Antisense and RNAi Therapeutics Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Oncology, 2021- 2031F |
6.1.4 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Cardiovascular Diseases (CVDs), 2021- 2031F |
6.1.5 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Respiratory Disorders, 2021- 2031F |
6.1.6 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Neurological Disorders, 2021- 2031F |
6.1.7 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.1.8 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Sweden Antisense and RNAi Therapeutics Market, By Technology |
6.2.1 Overview and Analysis |
6.2.2 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By RNA Interference, 2021- 2031F |
6.2.3 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Antisense RNA, 2021- 2031F |
6.3 Sweden Antisense and RNAi Therapeutics Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Pulmonary Delivery, 2021- 2031F |
6.3.3 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Intravenous Injections, 2021- 2031F |
6.3.4 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Intra-Dermal, 2021- 2031F |
6.3.5 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Intraperitoneal, 2021- 2031F |
6.3.6 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.7 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Sweden Antisense and RNAi Therapeutics Market, By End Users |
6.4.1 Overview and Analysis |
6.4.2 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Sweden Antisense and RNAi Therapeutics Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Sweden Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
7 Sweden Antisense and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 Sweden Antisense and RNAi Therapeutics Market Export to Major Countries |
7.2 Sweden Antisense and RNAi Therapeutics Market Imports from Major Countries |
8 Sweden Antisense and RNAi Therapeutics Market Key Performance Indicators |
8.1 Percentage of research and development (RD) budget allocated to RNAi and antisense therapeutics |
8.2 Number of clinical trials conducted for RNA-based therapies in Sweden |
8.3 Adoption rate of RNAi and antisense therapeutics by healthcare facilities in Sweden |
9 Sweden Antisense and RNAi Therapeutics Market - Opportunity Assessment |
9.1 Sweden Antisense and RNAi Therapeutics Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Sweden Antisense and RNAi Therapeutics Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.3 Sweden Antisense and RNAi Therapeutics Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Sweden Antisense and RNAi Therapeutics Market Opportunity Assessment, By End Users, 2021 & 2031F |
9.5 Sweden Antisense and RNAi Therapeutics Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Sweden Antisense and RNAi Therapeutics Market - Competitive Landscape |
10.1 Sweden Antisense and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Sweden Antisense and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here